Established in 2000, Novo A/S is the holding company of the Novo Group and is wholly owned by the Novo Nordisk Foundation. Novo A/S is the majority shareholder in the publicly listed companies, Novo Nordisk A/S and Novozymes A/S. Novo A/S provides seed, venture and growth capital to companies within life science and biotechnology. It also handles a broad portfolio of financial assets. In total, Novo A/S has more than USD 20 billion under management. Through Novo Ventures, Novo A/S invests venture capital in biotechnology and life science companies. Click here for more information: http://www.novo.dk.
MVM Life Science Partners
MVM was founded in 1997 and manages three funds totalling $500 million. MVM has invested in biopharmaceuticals, diagnostics, drug delivery, gene therapy, healthcare IT, healthcare services, medical devices, OTC medicines, research tools and vaccines. Current portfolio companies are based across Europe, Israel and in the US. The MVM team has broad experience across the life science and venture capital markets and maintains offices in London and Boston. Click here for more information: http://www.mvmlifescience.com.
SV Life Science Partners
SV Life Sciences is a leading international life sciences venture capital firm. SVLS affiliated funds have been investing in life sciences companies since the early 1980s and the firm closed its first dedicated life sciences fund in 1994. The SVLS team manages five private venture capital funds with approximately $2.0 billion of capital under management. The firm employs a diversified strategy within life sciences in order to selectively capitalize on an expanding opportunity in biotech, medical devices and healthcare services. SVLS has offices in Boston, London and San Francisco. Click here for more information: http://www.svlsa.com.